Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price shot up 8.2% during mid-day trading on Wednesday . The stock traded as high as $21.75 and last traded at $21.49. 91,333 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 223,354 shares. The stock had previously closed at $19.86.
Wall Street Analysts Forecast Growth
DNTH has been the subject of a number of research analyst reports. Oppenheimer lifted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a "buy" rating on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of "Buy" and an average price target of $46.83.
Read Our Latest Stock Report on DNTH
Dianthus Therapeutics Stock Performance
The business's fifty day moving average price is $22.56 and its two-hundred day moving average price is $25.02. The firm has a market capitalization of $711.22 million, a P/E ratio of -9.61 and a beta of 1.82.
Institutional Investors Weigh In On Dianthus Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MetLife Investment Management LLC lifted its position in Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after acquiring an additional 433 shares during the last quarter. Invesco Ltd. lifted its position in Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after acquiring an additional 790 shares during the last quarter. SG Americas Securities LLC lifted its position in Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock valued at $210,000 after acquiring an additional 814 shares during the last quarter. Barclays PLC lifted its position in Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company's stock valued at $933,000 after acquiring an additional 1,082 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Dianthus Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock valued at $3,641,000 after acquiring an additional 1,092 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
